Abstracts tagged "Work Participation"

Abstract Number: 0358 • ACR Convergence 2021
Work Participation in Patients with Axial Spondyloarthritis in Germany: Results from a Multicenter, Observational Survey
Uta Kiltz¹, Kirsten Hoeper², Ludwig Hammel³, Sebastian Lieb⁴, Andreas Haehle⁴ and Dirk Meyer-Olson⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Regionales Kooperatives Rheumazentrum Niedersachsen e. V.; Medizinische Hochschule Hannover, Department of Rheumatology and Immunology, Hannover, Germany,, Hannover, Germany, ³Deutsche Vereinigung Morbus Bechterew e.V.,, Schweinfurt, Germany, ⁴Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, ⁵m&i Fachklinik Bad Pyrmont, Hannover, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory condition often associated with impaired working participation1 not only translating to devastating outcomes for patients (pts) but…
Abstract Number: 0812 • ACR Convergence 2021
Are Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs Associated with Work Participation Improvement in Early Rheumatoid Arthritis? A Systematic Review and Meta-analysis
Mary Lucy Marques¹, Alessia Alunno², Louise Falzon³, Annelies Boonen⁴ and Sofia Ramiro¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University of Perugia, Perugia, Italy, ³Center for Personalized Health, Northwell Health, New York City, NY, ⁴Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands
Background/Purpose: Treatment of early RA with DMARDs is associated with particularly effective responses, resulting in sustained beneficial outcomes, including clinical and radiographic remission and optimal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].